Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
The prevalence rate of chronic hepatitis B and C among pulmonary TB patients Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Risk factors of drug -induced hepatitis among patients with TB/HIV co-infection Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity Source: International Congress 2015 – Screening strategies in TB Year: 2015
Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003
Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
Prevalence of hepatitis c virus infection among patients with COPD Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Source: Eur Respir J 2007; 29: 347-351 Year: 2007
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Frequency, severity and risk factors of drug-induced liver injury during treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001